Celldex Has Stellar Day; Acadia BioPharma Flat; 2 New Potential BioPharma Stocks – Ziopharm, and Capnia Inc.

Celldex Has Stellar Day; Acadia BioPharma Flat; 2 New Potential BioPharma Stocks – Ziopharm, and Capnia Inc.

http://www.fortunascorner.wordpress.com

Good evening to all, CellDex Theraputics (CLDX), a company that I have owned shares in for over a year, had a stellar day today — with shares rising $3.52, or 16.6 percent to $24.73. Nearly 9 million shares were traded; and, average daily volume is 2 million — so this surge upward occurred on high volume, which shows conviction and is a very good sign. The company announced FDA Breakthrough Therapy Designation for its rindopepimut (CDX-011) drug candidate for the treatment of adults with EGFRvlll-positive glioblastoma tumors. The company also has other experimental drug candidates in various stages of clinical trials — for breast and ovarian cancer. I added to my position in CLDX this morning at the market’s open. CLDX is expected to report fourth quarter earnings before the market open tomorrow morning (Feb. 24/Tue) and analysts believe the company will exceed expectations. Watch the tape in the morning before the open — pre-market trading will tell the tale on earnings. Having said that, if they miss and we get some selling, I will use that as an opportunity to add more shares tomorrow.

Acadia BioPharma (ACAD) is another long-term hold of mine, and the company’s pimavanserin drug for the treatement of Parkinson’s psychosis is currently in Phase III trials and is expected to get a thumbs up/thumbs down, from the FDA by the summer or early fall 2015. Pimavanserin is considered a First-In-Class Treatment for Parkinson’s psychosis; and, is in Phase II clinical trials for Alzheimers disease psychosis; and, has completed Phase II trials for pimavanserin for the treatment of schizophrenia. Finally, ACAD has clinical-stage programs for chronic pain and glaucoma — in collaboration with Allergan Inc., and two, advanced, preclinical programs directed at Parkinson’s disease and other neurological disorders. ACAD has been on a tear lately, up 11 percent last week; and, +40 percent year-to-date. Shares closed today up 17 cents, or .45 percent, to $37.62. The company is set to report fourth quarter earnings on Feb. 26.

There are two other bio-pharma/technology companies that I may get an investment footprint in tomorrow – Tues/Feb. 24, Capnia Inc. The first one — (CAPN) whose shares rose today $1.05, or 19.27 percent, to $6.50. The Redwood City, California-based company “focuses on the development of novel products for “precision metering of gas flow. On February 17, the company announced the first commercial sales of the Company’s CoSense End-Tidal Carbon Monoxide (ETCO) Monitors, and single-use sampling sets to leading academic, research, and health-care institutions. CoSense is a portable, non-invasive device that rapidly, and accurately measures carbon monoxide in exhaled breath.”

The final company that I may get an investment footprint in tomorrow is Ziopharm Oncology (ZIOP). Shares in ZIOP rose 50 cents today, or 5.23 percent, to $10.06, on 8.6M shares — average volume is 3 million. The Boston, Massachusetts-based bio-pharma company “engages in the discovery and development of drugs for the treatment of breast and melanoma.

This is what I am doing; but, remember — there are no guarantees in any of these investment plays/bets. Do your own due diligence, and homework. Make sure you have the risk tolerance, and done your own due diligence before you decide to invest in any of these companies Otherwise, good luck. V/R, RCP

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: